Compare Ecopetrol SA (EC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs 10X Genomics Inc — how do they compare? Ecopetrol SA trades at $17.06 (market cap $34.97B), while 10X Genomics Inc trades at $58.51 (market cap $7.64B). The key difference: Ecopetrol SA is far larger — about 4.6× 10X Genomics Inc's market cap, and Ecopetrol SA pays a 3.81% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| EC | TXG | |
|---|---|---|
Market Cap | $34.97B | $7.64B |
Sector | Energy | Health |
52-Week High | $17.40 | $58.57 |
52-Week Low | $8.53 | $11.34 |
Enterprise Value | $65.28B | $7.17B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.78, down 3.56% on the day, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators are neutral. Fundamentally, revenue and net income have declined from 2022 peaks, though Q2 2026 earnings beat expectations. Recent news includes a cybersecurity incident and expansion efforts in Brazil, adding to volatility. Valuation ratios like P/E of 11.11 and P/S of 0.97 suggest potential undervaluation relative to historical metrics.
The outlook for EC is cautious; analyst consensus is mixed with a $15 price target below the current price. Risks include declining revenue trends, high debt levels, and operational disruptions from recent cyber threats. Opportunities lie in cost management and strategic acquisitions, but investor sentiment remains divided. The stock's near-term performance hinges on execution stability and energy market conditions.
TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.
The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
